Class summary at a glance.

Every drug in the Melatonin Receptor Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $180.8Mcombined across class
Total Rx claims: 365K120K unique beneficiaries
Generic mfrs (active): 12across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tasimelteon

Brand: Hetlioz · 6K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2014-04-04

3 generic mfrs 235 plans require PA

Low NADAC$400.17

→

Avg plan cost$400.17

Part D spend $143.5M 1× spread, current vs floor

Class share

79%

of class CY24 spend

View profile →

Ramelteon

Brand: Rozerem · 359K Part D claims (CY24) · 119K beneficiaries · First FDA approval: 2005-07-22

9 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.717

→

Avg plan cost$1.59

Part D spend $37.4M 2× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.